Windtree’s Phase II Success In Cardiogenic Shock Could Lead To Heart Failure Opportunity

 
• By Joseph Haas
  
Heart failure care
Windtree hopes its novel drug will provide innovation in cardiogenic shock care • Source: Alamy

More from Clinical Trials

More from R&D